CTI BioPharma: NCCN Recommends VONJO For Myelofibrosis Patie

WASHINGTON (dpa-AFX) - CTI BioPharma Corp. (CTIC) said VONJO (pacritinib) has been included as a recommended treatment in the latest National Comprehensive Cancer Network Clinical Practice Guidelines

Related Keywords

Washington , United States , Adam Craig , Biopharma Corp , , Biopharma , Nccn , Ecommends , Honjo , Myelofibrosis , Patients , Regardless , Platelet , Count ,